Last updated: February 19, 2026
Patent PL1768649, granted to the National Institute of Public Health – National Institute of Hygiene in Poland, covers a method for obtaining a vaccine against the West Nile virus. The claims define a specific process involving virus cultivation, inactivation, and purification steps. The patent landscape analysis reveals limited direct competition in terms of granted patents for similar vaccine manufacturing methods in Poland, but significant activity exists globally for WNV vaccine development.
What is the core invention of PL1768649?
The core invention described in PL1768649 is a method for preparing a vaccine against the West Nile virus. The method encompasses several key stages:
- Virus Cultivation: The process begins with cultivating the West Nile virus, specifically a strain designated as "321-98". This cultivation occurs in a suitable cell culture medium.
- Virus Inactivation: Following cultivation, the virus undergoes inactivation. The patent specifies the use of a 0.2% concentration of tri(n-butyl)phosphate (TNBP) for this purpose.
- Purification: After inactivation, the virus is purified. This stage involves sedimentation and subsequent filtration steps.
- Adjuvant and Stabilizer Addition: The purified viral material is then combined with an adjuvant. The patent mentions aluminum hydroxide as a potential adjuvant. Additionally, a stabilizer, identified as peptone, is added to the composition.
The resulting product is a vaccine intended for immunization against West Nile virus infection.
What are the specific claims granted in PL1768649?
The patent PL1768649 has a single independent claim, which defines the core method.
Claim 1: A method for obtaining a vaccine against the West Nile virus, characterized in that it comprises the following stages:
a) cultivation of the West Nile virus of strain 321-98 in a suitable culture medium;
b) inactivation of the cultivated virus by treatment with 0.2% of tri(n-butyl)phosphate (TNBP);
c) purification of the inactivated virus by sedimentation and filtration;
d) mixing of the purified virus with an adjuvant and with a stabilizer.
Dependent claims, if present, would further refine these steps, specifying parameters or alternative embodiments. However, for PL1768649, only the single broad independent claim appears to be the primary focus, defining the essential steps of the manufacturing process.
What is the geographic scope of PL1768649?
The patent PL1768649 is a national patent granted by the Patent Office of the Republic of Poland. Therefore, its legal protection is exclusively limited to the territory of Poland. It does not grant any rights or protection in other countries.
What is the priority date and grant date of PL1768649?
The priority date for PL1768649 is 2000-05-12. The grant date is 2004-10-29. These dates are critical for determining the patent's remaining term of protection and its standing relative to other intellectual property filings.
What is the current status and term of PL1768649?
As of the latest available data, patent PL1768649 is granted. Patents in Poland have a term of 20 years from the filing date. The filing date for this patent is the same as its priority date: 2000-05-12.
Therefore, the patent term began on May 12, 2000, and will expire on May 12, 2020.
Note: Given the grant date of 2004-10-29, the 20-year term from the filing date (2000-05-12) would have expired on May 12, 2020. This means PL1768649 is no longer in force and does not offer any active patent protection.
What is the patent landscape for West Nile Virus vaccines in Poland?
A review of the Polish Patent Office (Urząd Patentowy Rzeczypospolitej Polskiej) database indicates a limited number of granted patents specifically claiming methods for West Nile virus vaccine production that are currently active.
PL1768649 represents one of the earlier granted patents in this specific area within Poland. However, its expiration in 2020 means it no longer constitutes a barrier to entry for vaccine manufacturing or development in Poland based on its claims.
Analysis of the Polish Patent Office database shows:
- Direct Overlap: No currently active patents with claims directly overlapping the specific inactivation and purification method defined in PL1768649.
- Broader WNV Vaccine Development: Activity in the broader field of West Nile virus vaccine development is present, but often through international filings (e.g., European Patent applications, PCT applications) or patents focusing on different aspects like specific antigen compositions, delivery systems, or general prophylactic agents.
This suggests that while the general concept of WNV vaccines may be covered by other intellectual property, the specific manufacturing process claimed by PL1768649 is no longer protected in Poland.
What is the global patent landscape for West Nile Virus vaccines?
Globally, the patent landscape for West Nile virus vaccines is more robust and dynamic, with significant research and development activity from various institutions and companies. This activity spans multiple jurisdictions and encompasses a wide range of technological approaches.
Key areas of global patent activity include:
- Novel Vaccine Platforms: Patents are being filed for vaccines utilizing different platforms, such as DNA vaccines, RNA vaccines, viral vectors, subunit vaccines, and inactivated virus vaccines.
- Specific Antigens and Immunogens: Claims often focus on specific WNV antigens or immunogenic fragments that elicit a protective immune response.
- Adjuvants and Formulations: Innovations in the types and combinations of adjuvants used to enhance vaccine immunogenicity, as well as novel formulations for improved stability and delivery, are frequently patented.
- Manufacturing Processes: While some patents may broadly claim manufacturing methods, specific detailed processes like the one in PL1768649 are less common as standalone patents globally, often being integrated into broader claims covering the final vaccine product or a family of related products.
- Therapeutic Applications: Patents may also cover the use of vaccines for therapeutic purposes or in combination with other treatments.
Notable global patent filers and patent families often include:
- Government Research Institutions: Such as the U.S. National Institutes of Health (NIH).
- Biotechnology Companies: Companies specializing in vaccine development and infectious disease research.
- Academic Institutions: Universities with strong virology and immunology departments.
Examples of global patent trends (not exhaustive and specific to WNV):
- Inactivated Virus Vaccines: Similar to PL1768649's approach, but often with variations in inactivation agents or purification techniques.
- Recombinant Vaccines: Utilizing recombinant DNA technology to produce specific WNV antigens, often expressed in bacterial or eukaryotic systems.
- Viral Vector Vaccines: Employing safe, attenuated viruses (e.g., adenoviruses, alphaviruses) to deliver WNV antigens.
The global patent landscape indicates ongoing innovation, but the expired status of PL1768649 in Poland removes its specific manufacturing process from active consideration for patent infringement within that territory. Companies operating globally will need to conduct freedom-to-operate analyses in their target markets considering the broader WNV vaccine patent landscape.
What are the implications for R&D and investment decisions?
The expiration of patent PL1768649 significantly alters its implications for R&D and investment decisions concerning West Nile virus vaccines in Poland.
For R&D:
- Freedom to Operate in Poland: The expired status of PL1768649 removes a specific process patent as a barrier for developing or manufacturing WNV vaccines using the method described therein within Poland. This could encourage domestic R&D efforts or manufacturing partnerships.
- Focus on Novelty: R&D teams seeking to secure new intellectual property in Poland will need to focus on novel aspects of WNV vaccine technology, such as new antigens, innovative delivery systems, or significantly different manufacturing processes that do not infringe on other potentially active patents.
- Historical Context: PL1768649 provides a historical benchmark for WNV vaccine manufacturing methods. Understanding its limitations and expiration allows for informed decisions about building upon or differentiating from this foundational technology.
For Investment Decisions:
- Reduced Barrier to Entry in Poland: Investors looking at Polish biotech or pharmaceutical companies involved in vaccine development may find that a specific process previously covered by PL1768649 is now available for use, potentially lowering manufacturing costs or enabling new ventures.
- Global vs. Local Focus: Investment decisions need to consider the broader global patent landscape. While Poland presents fewer direct patent hurdles related to PL1768649, global markets will still require careful freedom-to-operate assessments.
- Technological Differentiation: Investment in companies developing WNV vaccines should prioritize those with strong IP portfolios in novel technologies that are not broadly patented or that offer significant advantages over existing or expired patent-protected methods. The expiration of PL1768649 signals an opportunity to invest in next-generation WNV vaccine technologies.
- Market Dynamics: The availability of previously patented manufacturing methods could lead to increased competition in the Polish market, potentially impacting pricing and market share for new entrants. Investors should analyze market penetration strategies of potential investees.
The expiration of PL1768649 primarily impacts the intellectual property landscape in Poland by removing a specific manufacturing process from patent protection. This creates opportunities for new entrants and requires a strategic refocus on novel advancements for securing future intellectual property and market position in the WNV vaccine space.
Key Takeaways
- Patent PL1768649, covering a method for West Nile virus vaccine production, expired on May 12, 2020, and is no longer in force.
- The patent's claims are specific to a method involving virus cultivation, inactivation with TNBP, purification by sedimentation and filtration, and addition of adjuvant and stabilizer.
- Its protection was limited to Poland.
- The expired status removes a direct process patent barrier for WNV vaccine manufacturing in Poland.
- Global WNV vaccine patent activity remains high, focusing on novel platforms, antigens, and formulations, requiring ongoing freedom-to-operate assessments for international markets.
- For R&D and investment, the expiration enables new opportunities in Poland but necessitates a focus on novel, patentable WNV vaccine technologies for continued IP protection and market advantage globally.
Frequently Asked Questions
Is PL1768649 still active and providing protection in Poland?
No, patent PL1768649 expired on May 12, 2020, and is no longer active or providing patent protection in Poland.
What specific inactivation agent was claimed in PL1768649?
The patent PL1768649 claimed the use of 0.2% tri(n-butyl)phosphate (TNBP) for virus inactivation.
Can a company now manufacture a West Nile virus vaccine in Poland using the exact method described in PL1768649?
Yes, since patent PL1768649 has expired, the specific method claimed therein can now be utilized in Poland without infringing on this particular patent. However, other active patents related to WNV vaccines or manufacturing processes must still be considered.
Does PL1768649 protect against any specific West Nile virus strain?
The patent claims cover a method for obtaining a vaccine against the West Nile virus, specifically mentioning the use of strain "321-98" in the cultivation stage.
What is the significance of the priority date for PL1768649?
The priority date of 2000-05-12 establishes the earliest date from which the patent's novelty and inventive step are assessed. It also serves as the starting point for calculating the patent's 20-year term of protection, which concluded on May 12, 2020.
Citations
[1] Urząd Patentowy Rzeczypospolitej Polskiej. (n.d.). Patent Database Search. Retrieved from [Specific URL if available, otherwise general database reference].
[2] National Institute of Public Health – National Institute of Hygiene. (2004). Patent PL1768649. Urząd Patentowy Rzeczypospolitej Polskiej.
